Suzanne A Eccles,Eric O Aboagye,Simak Ali,Annie S Anderson,Jo Armes,Fedor Berditchevski,Jeremy P Blaydes,Keith Brennan,Nicola J Brown,Helen E Bryant,Nigel J Bundred,Joy M Burchell,Anna M Campbell,Jason S Carroll,Robert B Clarke,Charlotte E Coles,Gary JR Cook,Angela Cox,Nicola J Curtin,Lodewijk V Dekker,Isabel dos Santos Silva,Stephen W Duffy,Douglas F Easton,Diana M Eccles,Dylan R Edwards,Joanne Edwards,D Gareth Evans,Deborah F Fenlon,James M Flanagan,Claire Foster,William M Gallagher,Montserrat Garcia-Closas,Julia M W Gee,Andy J Gescher,Vicky Goh,Ashley M Groves,Amanda J Harvey,Michelle Harvie,Bryan T Hennessy,Stephen Hiscox,Ingunn Holen,Sacha J Howell,Anthony Howell,Gill Hubbard,Nick Hulbert-Williams,Myra S Hunter,Bharat Jasani,Louise J Jones,Timothy J Key,Cliona C Kirwan,Anthony Kong,Ian H Kunkler,Simon P Langdon,Martin O Leach,David J Mann,John F Marshall,Lesley Ann Martin,Stewart G Martin,Jennifer E Macdougall,David W Miles,William R Miller,Joanna R Morris,Sue M Moss,Paul Mullan,Rachel Natrajan,James PB O’Connor,Rosemary O’Connor,Carlo Palmieri,Paul D P Pharoah,Emad A Rakha,Elizabeth Reed,Simon P Robinson,Erik Sahai,John M Saxton,Peter Schmid,Matthew J Smalley,Valerie Speirs,Robert Stein,John Stingl,Charles H Streuli,Andrew N J Tutt,Galina Velikova,Rosemary A Walker,Christine J Watson,Kaye J Williams,Leonie S Young,Alastair M Thompson

Abstract:IntroductionBreast cancer remains a significant scientific, clinical and societal challenge. This gap analysis has reviewed and critically assessed enduring issues and new challenges emerging from recent research, and proposes strategies for translating solutions into practice.MethodsMore than 100 internationally recognised specialist breast cancer scientists, clinicians and healthcare professionals collaborated to address nine thematic areas: genetics, epigenetics and epidemiology; molecular pathology and cell biology; hormonal influences and endocrine therapy; imaging, detection and screening; current/novel therapies and biomarkers; drug resistance; metastasis, angiogenesis, circulating tumour cells, cancer ‘stem’ cells; risk and prevention; living with and managing breast cancer and its treatment. The groups developed summary papers through an iterative process which, following further appraisal from experts and patients, were melded into this summary account.ResultsThe 10 major gaps identified were: (1) understanding the functions and contextual interactions of genetic and epigenetic changes in normal breast development and during malignant transformation; (2) how to implement sustainable lifestyle changes (diet, exercise and weight) and chemopreventive strategies; (3) the need for tailored screening approaches including clinically actionable tests; (4) enhancing knowledge of molecular drivers behind breast cancer subtypes, progression and metastasis; (5) understanding the molecular mechanisms of tumour heterogeneity, dormancy, de novo or acquired resistance and how to target key nodes in these dynamic processes; (6) developing validated markers for chemosensitivity and radiosensitivity; (7) understanding the optimal duration, sequencing and rational combinations of treatment for improved personalised therapy; (8) validating multimodality imaging biomarkers for minimally invasive diagnosis and monitoring of responses in primary and metastatic disease; (9) developing interventions and support to improve the survivorship experience; (10) a continuing need for clinical material for translational research derived from normal breast, blood, primary, relapsed, metastatic and drug-resistant cancers with expert bioinformatics support to maximise its utility. The proposed infrastructural enablers include enhanced resources to support clinically relevant in vitro and in vivo tumour models; improved access to appropriate, fully annotated clinical samples; extended biomarker discovery, validation and standardisation; and facilitated cross-discipline working.ConclusionsWith resources to conduct further high-quality targeted research focusing on the gaps identified, increased knowledge translating into improved clinical care should be achievable within five years.

Imaging biomarker roadmap for cancer studies

A roadmap for the clinical implementation of optical-imaging biomarkers

A Systematic Approach to Biomarker Discovery; Preamble to "the Isbtc-Fda Taskforce on Immunotherapy Biomarkers"

Image‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer

Biomarkers and Imaging of Breast Cancer

Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials

Imaging Biomarkers in Prostate Stereotactic Body Radiotherapy: A Review and Clinical Trial Protocol

Emerging Concepts in Biomarker Discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.

Co-Clinical Imaging Metadata Information (CIMI) for Cancer Research to Promote Open Science, Standardization, and Reproducibility in Preclinical Imaging

Imaging biomarkers for clinical applications in neuro-oncology: current status and future perspectives

Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups

Imaging-guided precision medicine in glioblastoma patients treated with immune checkpoint modulators: research trend and future directions in the field of imaging biomarkers and artificial intelligence

Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer

Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine

The Society for Immunotherapy of Cancer Perspective on Tissue-Based Technologies for Immuno-Oncology Biomarker Discovery and Application

Minimally Invasive Pharmacokinetic and Pharmacodynamic Technologies in Hypothesis-Testing Clinical Trials of Innovative Therapies

The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice

Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours

Molecular Imaging Biomarkers in Cardiooncology: A View on Established Technologies and Future Perspectives

Molecular Imaging Biomarkers for Early Cancer Detection: A Systematic Review of Emerging Technologies and Clinical Applications